| WO2021155149 |
Genentech, USA; BioNTech SE, Germany; F. Hoffmann-La
Roche,
Switzerland |
Methods of inducing neoepitope-specific
T cells with a PD-1
axis binding antagonist and an RNA vaccine |
| WO2015024664 |
CureVac,
Germany |
Composition comprising mRNA encoding a combination
of tumor
antigens as vaccine for treating prostate cancer |
| WO2012019168 |
ModernaTX,
USA |
Use of modified mRNA encoding melanocyte stimulating
hormone,
insulin and granulocyte colony-stimulating factor in prevention or
treatment of disorders |
| WO2020097291 |
ModernaTX, USA |
Cancer vaccines comprising
mRNA(s) encoding peptide epitopes
(neoepitopes) and formulated as lipid nanoparticles |
| WO2020141212 |
eTheRNA
Immunotherapies NV, Belgium |
mRNA vaccine |
| WO2022008519 |
BioNTech SE, Germany; TRON – Translationale Onkologie
Mainz, Germany |
Therapeutic RNA for HPV-positive cancer |
| WO2015024666 |
CureVac, Germany |
RNA vaccine for treating lung
cancer |
| WO2012159643 |
BioNTech AG, Germany; TRON – Translationale
Onkologie
Mainz, Germany |
Individualized vaccines for cancer |
| WO2015014869 |
BioNTech AG, Germany; TRON – Translationale Onkologie
Mainz, Germany |
Determination of expression pattern of
a set of tumor antigens
including Cxorf61, CAGE1, PRAME and others to select cancer therapy
regimen |
| WO2022009052 |
Janssen Biotech, USA |
Prostate neoantigens
and their uses |
| WO2022081764 |
RNAimmune, USA |
Pan-ras mRNA cancer vaccines |
| WO2014082729 |
BioNTech AG, Germany; Mainz Gemeinnuetzige GmbH, Germany |
Individualized vaccines for cancer |
| WO2016180467 |
BioNtech
Cell & Gene Therapies, Germany; TRON –
Translationale Onkologie Mainz, Germany |
Enhancing the
effect of car-engineered T cells by means of
nucleic acid vaccination |
